Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid
about
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and childrenRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with formoterol for chronic asthma: serious adverse eventsAddition to inhaled corticosteroids of long-acting beta 2-agonists versus anti-leukotrienes for chronic asthmaRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsCombination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and childrenRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenFormoterol versus short-acting beta-agonists as relief medication for adults and children with asthmaCombination formoterol and inhaled steroid as maintenance and reliever therapy versus higher dose combination inhaler maintenance for chronic asthma in adults and childrenFormoterol versus short-acting beta-agonists as relief medication for chronic asthmaAddition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in childrenAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenRegular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse eventsCombination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and childrenCombination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and childrenRegular treatment with salmeterol for chronic asthma: serious adverse eventsCombination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and childrenCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCombination inhaled steroid and long-acting beta-agonist versus fast-acting beta agonist as relief medication for chronic asthma in adults and childrenOral xanthines as maintenance treatment for asthma in childrenLong-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studiesGuidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendationsRates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: an exploratory post-hoc analysis.An integrative review of systematic reviews related to the management of breathlessness in respiratory illnessesA human surfactant peptide-elastase inhibitor construct as a treatment for emphysema.Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma.Long-Acting Beta Agonists Enhance Allergic Airway DiseaseFactors related to under-diagnosis and under-treatment of childhood asthma in metropolitan France.Long-acting beta-agonists and the risk of intensive care unit admission in children.Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study.Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.Current challenges in asthma.Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed.
P2860
Q24197662-0B0B5EE8-F4D5-4E04-B50A-7BDDB3A6BE18Q24199079-B6BE89D9-5912-4118-920E-0FF36570913AQ24200353-C114774D-F18E-4A4B-B236-4CE1907891E3Q24200999-FC7C8B09-AD3B-4ABD-B440-C5CD6812EF3FQ24201048-52E3AB7C-5585-41C7-B390-48992328F2A6Q24201774-C037DADB-9B06-4F7C-95C3-67A39D31C46AQ24202005-994BED11-85D8-4DE1-AB55-EB7263CFB024Q24202510-8BDA8B87-65DA-4362-919D-4389AA1F0A2BQ24234499-CE63DDBC-C35D-41D8-ABEF-81B0CD743EA0Q24234581-37208067-7B88-428C-90A0-11C8E8A836E3Q24235303-D6963699-114C-497D-A9C6-9460807077CAQ24235496-D67539E2-F390-4B8B-80A8-1CE354DD4A3FQ24236220-AE977F7A-8A72-45D0-97BA-08339FB65A9AQ24239826-15594D4A-4512-43BC-ABC5-8C924A6970DAQ24239922-F8F5699A-452D-4646-B129-497FDC3580D0Q24240464-208D4B72-F2CC-4780-826A-2788B2841077Q24240832-05156BD4-78EC-478E-AAE7-A2C669DF2077Q24241025-B332A882-CFEE-4604-80C1-C949402CDA03Q24241556-C3370841-69FC-4618-A7E5-DFDB99A4D495Q24241960-B2F0F99C-D37C-4329-A4FA-B41079932B5CQ24242173-A3E18D40-DDF9-4D4D-80FA-C955D1DAB651Q24243564-C799CC1C-1963-4F09-A3F4-60D767A40B67Q24243635-54F5B864-7F67-4561-98FC-EEF2B70F05E1Q24244588-8691AFFC-5F58-4620-BB3D-C246ACB6006BQ27027449-B5E7C7C2-879D-4B0E-87EC-49A6209FCE24Q28392274-460A808B-EA5A-4DB1-BCAD-CB4CA54A27C1Q33424090-535F8242-E634-4238-97D2-89CA76183DA8Q33766956-578DCFC0-0860-440B-B71D-28E4C4CD4A6DQ33934859-A827211C-D2CC-4858-B6A3-A0C41FA4927BQ35818440-BE4D859E-00AE-4579-AF83-98747C38C54FQ35852118-D34A378A-DB85-4BB3-9F51-468E2048A91AQ36217749-71E9485D-A808-4963-9658-C62A13863459Q36912259-F334F3C1-A2F5-4380-A72C-807B756CB1CDQ37184413-BD65F083-45CF-4DC0-8322-A0566722F99DQ38817408-47F1B469-D309-4730-BD43-EC0164253179Q39037235-2581A754-9DFD-450D-A2FB-EB79EDE025AEQ42624152-4B64270F-00C8-40BF-9417-E6B888F15FADQ47657351-6425521F-5DB2-4ADA-962A-B539222A6C24
P2860
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@ast
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@en
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@en-gb
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@nl
type
label
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@ast
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@en
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@en-gb
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@nl
prefLabel
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@ast
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@en
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@en-gb
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@nl
P2093
P2860
P1476
Long-acting beta2-agonists for ...... d or no inhaled corticosteroid
@en
P2093
E H Walters
J A E Walters
T J Lasserson
P2860
P304
P356
10.1002/14651858.CD001385.PUB2
P577
2007-01-24T00:00:00Z